Word: genentech
(lookup in dictionary)
(lookup stats)
Dates: all
Sort By: most recent first
(reverse)
...next week, including trips to Norway and the Russian city of Murmansk. RECOVERING. LES PAUL, 80, musician and father of the electric guitar; after collapsing while preparing to travel to a Nashville birthday concert; in Mahwah, New Jersey. OUSTED. G. KIRK RAAB, 59, president and ceo of biotech giant Genentech; following the revelation that he had requested a personal $2 million loan guarantee from Roche Holding Ltd. while negotiating a merger with the firm; in San Francisco. During Raab's five years at Genentech, the company's revenues nearly doubled. But shareholders have been growing restive over earnings...
...biggest reason TPA took off was the aggressive promotional campaign launched by its manufacturer, Genentech. The worldwide market for anticlotting agents, or thrombolytics, is estimated at $600 million a year. To get a substantial piece of the action, Genentech relentlessly promoted its product not just to doctors and patients but to researchers as well. "I have never seen anything like it," said Dr. Charles Hennekens, U.S. coordinator for the study released last week...
...Genentech, Hennekens says, refused to participate in the international study, which compared TPA with streptokinase and a third thrombolytic called anistreplase, so a British-made version of TPA was used instead. Moreover, Hennekens says, when he tried to recruit doctors to participate, he found that some had been told by Genentech salesmen that using the other drugs in the trial could endanger their patients. Streptokinase, they were told, could cause cerebral bleeding, and anistreplase, which is derived from human plasma, was alleged to carry a risk of AIDS infection. Neither danger is significant, said Hennekens. Genentech denied any direct meddling...
...genome, then -- as better technology became available -- proceed to reading the entire genetic message. Most of the remaining critics were silenced last fall when the NIH chose the respected Watson as project director. Still, some scientists remain wary of the project. Says David Botstein, a vice president at Genentech and a member of the Human Genome Advisory Committee: "We need to test its progress, regulate its growth and slap it down if it becomes a monster. Jim Watson understands the dangers as well...
Developed by South San Francisco's Genentech, Inc., the CD4 currently in clinical trials is a copy of a protein that is anchored in the surface of cells known as T-4 lymphocytes. These cells are a pillar of the immune system and a key target for the AIDS virus. Natural CD4 attracts gp120, a molecule on the surface of the AIDS virus. In the usual course of the disease, the virus uses the natural CD4 to attach itself to a T-4 cell, which it invades and ultimately destroys. Synthetic CD4, however, acts as a decoy by latching onto...